hydrolase/neoplasms

BACKGROUND A major challenge facing biological researchers in the 21.sup.st century is the functional characterization of the large number of unannotated gene products identified by genome sequencing efforts. Many proteins partly or completely uncharacterized with respect to their biochemical

BACKGROUND OF THE INVENTION The field of the invention is modulation of drug resistance. The concentrations of proteins in biological cells are regulated by elegant biochemical mechanisms. By way of these mechanisms, cells eliminate damaged proteins and can, by altering the concentrations of

BACKGROUND OF THE INVENTION The field of the invention is modulation of drug resistance. The concentrations of proteins in biological cells are regulated by elegant biochemical mechanisms. By way of these mechanisms, cells eliminate damaged proteins and can, by altering the concentrations of

BACKGROUND OF THE INVENTION SAH hydrolase has been an attractive target for antiviral drug design based on the observation that many viruses require 5'-capped, methylated structures on their mRNA for efficient translation of viral proteins. Yuan et al., Exp. Opin. Ther. Patents, 9: 1197-1206 (1999);

BACKGROUND OF THE INVENTION SAH hydrolase has been an attractive target for antiviral drug design based on the observation that many viruses require 5'-capped, methylated structures on their mRNA for efficient translation of viral proteins. Yuan et al., Exp. Opin. Ther. Patents, 9: 1197 1206 (1999);

BACKGROUND OF THE INVENTION SAH hydrolase has been an attractive target for antiviral drug design based on the observation that many viruses require 5'-capped, methylated structures on their mRNA for efficient translation of viral proteins. Yuan et al., Exp. Opin. Ther. Patents, 9: 1197-1206 (1999);

FIELD OF THE INVENTION The present invention is directed toward the production of Acyl-Peptide Hydrolase by recombinant DNA technology. It is also directed to the use of the enzyme to catalyze hydrolysis of an acylated peptide or protein, and the reaction between a derivatized N.sup..alpha. -acetyl

TECHNICAL FIELD This invention relates generally to certain nucleoside analogues, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to

FIELD OF THE INVENTION The present invention relates generally to the peptidase gamma glutamyl hydrolase, and more particularly to nucleic acid molecules encoding gamma glutamyl hydrolase and uses thereof. BACKGROUND OF THE INVENTION Throughout this application various publications are referenced,

FIELD OF THE INVENTION The present invention relates generally to the peptidase gamma glutamyl hydrolase, and more particularly to nucleic acid molecules encoding gamma glutamyl hydrolase and uses thereof. BACKGROUND OF THE INVENTION Throughout this application various publications are referenced,

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application of PCT/GB2016/052130 filed Jul. 14, 2016, which claims priority from UK Patent Application No. 1512270.8, filed on Jul. 14, 2015 and UK Patent Application No. 1604642.7, filed on Mar. 18, 2016. The priority of

SEQUENCE LISTING This application contains a Sequence Listing that is being submitted herewith as a separate document. BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is in the field of cancer therapy and in particular, relates to compositions and methods to specifically kill

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is in the field of cancer therapy and in particular, relates to compositions and methods to specifically kill tumor cells by the production of toxic compounds in the tumor cells. 2. Description of the Related Art Inefficiency of

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application of PCT/GB2017/050763 filed Mar. 17, 2017, which claims priority from UK Patent Application. No. 1604647.6, filed on Mar. 18, 2016. The priority of said PCT and UK Patent Application are claimed. Each of the

TECHNICAL FIELD The present invention relates to methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancers and selecting patients for treatment based for increased sensitivity to 10-propargyl-10-deazaaminopterin. SEQUENCE INCORPORATED BY REFERENCE Incorporated